MedTrace Logo

A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

NCT02897115 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-07-05

Study results available
· View outcomes & findings →

Summary

A study comparing a treat-to-target (T2T) intense treatment approach with routine treatment (Standard of Care \[SOC\]) in reducing disease activity in participants with axial spondyloarthritis (axSpA).

Conditions

  • Axial Spondyloarthritis

Interventions

BIOLOGICAL

Adalimumab

Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.

OTHER

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

ASAS recommended NSAID doses to treat axial spondyloarthritis.

Sponsors & Collaborators

  • IST GmbH, Germany

    collaborator INDUSTRY

  • Hannover Medical School

    collaborator OTHER

  • Improvement by Movement GmbH, Germany

    collaborator UNKNOWN

  • AbbVie

    lead INDUSTRY

Principal Investigators

  • AbbVie Inc. · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-12
Primary Completion
2017-12-21
Completion
2017-12-21

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02897115 on ClinicalTrials.gov